Table of Contents

2024-9-12

Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors—first cohort from the EADV Task Force ‘Dermatology for Cancer Patients’

2024-9-12

Editorial Board

2024-9-12

Optimizing Rectal Cancer Treatment: A Path Towards Personalization

2024-9-12

CN21 Descriptive and content analysis of breast cancer vlogs on YouTube

2024-9-1

778P Efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure: A prospective, open label, single-arm, phase II study

2024-9-1

642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC

2024-9-1

CN82 Nurses management of malnutrition risk in cancer patients: The importance of screening tools

2024-9-1

810MO Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: A phase l/II study

2024-9-1

432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04

2024-9-1

247P Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis

2024-9-1

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

2024-9-1

CN34 Suicide and digestive cancer: A systematic review

2024-9-1

150P Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers

2024-9-1

1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC

2024-9-1

782P Predicting survival in malignant struma ovarii (MSO): A machine learning approach

2024-9-1

1378P Improvements in stage IV non-small cell lung cancer survival differ by race in the US

2024-9-1

219P The landscape and prognostic impact of germline HLA-A subtypes in patients with advanced solid cancers

2024-9-1

CN66 Healthcare needs, experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland

2024-9-1

614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification

2024-9-1

57P Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer

2024-9-1

1893P Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers

2024-9-1

496P Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients

2024-9-1

489P Interfering with the tumor microenvironment of glioblastoma: An in vitro study

2024-9-1

977P Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: A multicenter cohort study

2024-9-1

CN43 Comprehensive pan-cancer exploration of the ubiquitin-proteasome system: A bidirectional Bayesian Weighted Mendelian randomization study

2024-9-1

1557P The use of patient experience in UK NICE decision making in oncology

2024-9-1

CN98 The health gains of therapeutic touch in cancer patients with pain: A literature review

2024-9-1

2019P Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe

2024-9-1

1393TiP A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)

2024-9-1

1331P Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)

2024-9-1

674P Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs

2024-9-1

1882P Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey

2024-9-1

265P Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy

2024-9-1

1898P Efficacy of virtual reality-based interventions in cancer-related symptom management in AYA's: A systematic review

2024-9-1

1490P Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study

2024-9-1

1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study

2024-9-1

CN104 Exercise interventions in the management of chemotherapy-induced peripheral neuropathy

2024-9-1

1332P Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases

2024-9-1

1547P Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)

2024-9-1

1381P Comparison between standard dose 75mg/m2 and fixed dose at 50mg of cisplatin in the treatment of non-small cell lung cancer patients in term of response rate and toxicity profile

2024-9-1

1364P Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE)

2024-9-1

1396TiP Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial

2024-9-1

1344P Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations

2024-9-1

819P Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression

2024-9-1

1047P Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis

2024-9-1

800MO First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study

2024-9-1

308P Impact of the COVID-19 (C19) pandemic on breast cancer (BC) treatment patterns in the US

2024-9-1

362P Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors

2024-9-1

1984P Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial

2024-9-1